Company: BIAF
Filing Date: 2025-05-02
Form Type: S-1
Source: 0001641172-25-008170
Chunk: 85

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-05-02
Form: S-1
Chunk 85
---
arrant would increase (decrease) the as adjusted net tangible book value by $684,000 per share of Common Stock and the dilution to new investors by $0.319 per share, after deducting the estimated Placement Agent fees and estimated offering expenses payable by us.

We may also increase or decrease the number of shares we are offering. An increase of 1,000,000 shares in the number of shares of Common Stock offered by us would increase our as adjusted net tangible book value by approximately $0.5 million, or approximately $0.01 per share of Common Stock, and decrease the dilution per share to investors in this offering by approximately $0.01 per share, assuming that the number of shares of Common Stock and accompanying April 2025 Warrants offered by us, as set forth on the cover page of this prospectus, remains the same, and after deducting the estimated Placement Agent fees and estimated offering expenses payable by us. Similarly, a decrease of 1,000,000 shares in the number of shares of Common Stock offered by us would decrease our as adjusted net tangible book value by approximately $0.5 million, or approximately $0.01 per share, and increase the dilution per share to investors in this offering by approximately $0.01 per share, assuming the assumed combined offering price of $0.499 per share of Common Stock and accompanying April 2025 Warrant remains the same and after deducting the estimated Placement Agent fees and estimated offering expenses payable by us. The information discussed above is illustrative only and will be adjusted based on the actual public offering price and other terms of this offering as determined between us and the Placement Agent at pricing.

The information above is based on 15,576,674 shares of Common Stock outstanding as of December 31, 2024, and excludes, as of that date:

| ● | 12,298,124                                                                                         
 shares of Common Stock issuable upon the exercise of outstanding warrants with a weighted          
 average exercise price equal to $2.95 per share;                                                   |
| ● | 304,125                                                                                            
 shares                                                                                             
 of Common Stock issuable upon the exercise of stock options issued under our equity incentive      
 plans with a weighted average exercise price equal to $6.95 per share;                             |
| ● | 1,480,208                                                                                          
 shares of our Common Stock that are reserved for equity awards that may be granted under           
 our 2024 Equity Incentive Plan;                                                                    |
| ● | 75